Andreas Reiter

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
    Andreas Reiter
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Cancer Res 65:2662-7. 2005
  2. ncbi AraC-based pharmacotherapy of chronic myeloid leukaemia
    A Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin der Universtät Heidelberg, Germany
    Expert Opin Pharmacother 2:1129-35. 2001
  3. ncbi Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia
    Andreas Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Acta Haematol 112:55-67. 2004
  4. ncbi Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders
    Andreas Reiter
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Str 7 11, 68305 Mannheim, Germany
    Curr Drug Targets 8:205-16. 2007
  5. doi Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 143:707-15. 2008
  6. doi Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia
    Christoph Walz
    Pathologisches Institut, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    Genes Chromosomes Cancer 49:471-9. 2010
  7. ncbi Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene
    Christoph Walz
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str 7 11 68305 Mannheim, Germany
    Haematologica 92:163-9. 2007
  8. ncbi Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene
    Christoph Walz
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Genes Chromosomes Cancer 45:950-6. 2006
  9. doi Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
    Kirsten Merx
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 92:907-15. 2013
  10. ncbi Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
    Andreas Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin der Universität Heidelberg, Germany
    Genes Chromosomes Cancer 36:175-88. 2003

Detail Information

Publications49

  1. ncbi The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
    Andreas Reiter
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Cancer Res 65:2662-7. 2005
    ..We conclude that human autoantigen pericentriolar material (PCM1)-JAK2 is a novel, recurrent fusion gene in hematologic malignancies. Patients with PCM1-JAK2 disease are attractive candidates for targeted signal transduction therapy...
  2. ncbi AraC-based pharmacotherapy of chronic myeloid leukaemia
    A Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin der Universtät Heidelberg, Germany
    Expert Opin Pharmacother 2:1129-35. 2001
    ..The clinical benefits may therefore be outweighed by the dose-limiting toxicity for both application forms. Combinations with other drugs, e.g., STI571 or homoharringtonine, have shown promising early results in vitro and in vivo...
  3. ncbi Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia
    Andreas Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Acta Haematol 112:55-67. 2004
    ..Quantitative RT-PCR technology is expected to further improve the predictive value of MRD monitoring and therefore to guide therapy in order to reduce the rate of relapses and to increase rates of cure in high-risk patients...
  4. ncbi Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders
    Andreas Reiter
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Str 7 11, 68305 Mannheim, Germany
    Curr Drug Targets 8:205-16. 2007
    ..Other inhibitors under development are promising candidates for effective treatment of patients with constitutive activation of JAK2, FGFR1 and imatinib-resistant KIT mutants...
  5. doi Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Br J Haematol 143:707-15. 2008
    ..These data confirmed the long-term efficacy of imatinib for PDGFR-rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib...
  6. doi Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia
    Christoph Walz
    Pathologisches Institut, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    Genes Chromosomes Cancer 49:471-9. 2010
    ..This study demonstrates that the frequency of RARA-PML expression has been underestimated and highlights remarkable complexity at chromosomal breakpoint regions in APL even in cases with an apparently simple balanced t(15;17)(q24;q12)...
  7. ncbi Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene
    Christoph Walz
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str 7 11 68305 Mannheim, Germany
    Haematologica 92:163-9. 2007
    ....
  8. ncbi Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene
    Christoph Walz
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Genes Chromosomes Cancer 45:950-6. 2006
    ....
  9. doi Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study
    Kirsten Merx
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 92:907-15. 2013
    ..In six investigated patients, no significant reduction of the JAK2V617F burden was observed despite clinical improvement. The results show that imatinib has moderate cytoreductive effects in PV...
  10. ncbi Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia
    Andreas Reiter
    III Medizinische Universitätsklinik, Klinikum Mannheim, Fakultät für Klinische Medizin der Universität Heidelberg, Germany
    Genes Chromosomes Cancer 36:175-88. 2003
    ..These findings are consistent with the hypothesis that the t(15;17) occurs by nonhomologous recombination of DNA after processing of the double-strand breaks by a dysfunctional DNA damage-repair mechanism...
  11. doi Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
    Alice Fabarius
    Medizinische Universitatsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Blood 118:6760-8. 2011
    ..001) than in patients with standard t(9;22). We conclude that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis...
  12. doi Activating CBL mutations are associated with a distinct MDS/MPN phenotype
    Juliana Schwaab
    III Medizinische Klinik, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Ann Hematol 91:1713-20. 2012
    ..Nine deaths (progression to secondary acute myeloid leukemia/blast phase, n = 7; cytopenia complications, n = 2) were recorded. Three-year survival rate was 27%, possibly indicating poor prognosis of CBL mutated MDS/MPN patients...
  13. doi The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
    Philipp Erben
    III Medizinische Klinik, Universitatsmedizin Mannheim, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
    Ann Hematol 93:81-8. 2014
    ..We therefore conclude that RQ-PCR assays for KIT D816V are useful complimentary tools for diagnosis, disease monitoring, and evaluation of prognosis in patients with SM...
  14. ncbi Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha
    U Berger
    Klinikum Mannheim, Universitat Heidelberg, Mannheim, Germany
    Leukemia 17:1820-6. 2003
    ..We conclude that the course of CML is not different in the elderly. They require lower IFN doses, achieve the same hematologic and cytogenetic response rates and the same survival advantage at comparable toxicity...
  15. doi Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity
    Georgia Metzgeroth
    III Medizinische Klinik, Universitätsmedizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Onkologie 33:263-9. 2010
    ..Despite temporary clinical improvement, he died 6 months after the diagnosis. The diagnostic panel of HAC should include AFP, HepPar1, and EpCAM antibodies. EpCAM reactivity excludes HCC. HAC has a poor prognosis...
  16. ncbi Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
    Rudiger Hehlmann
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 63805 Mannheim, Germany
    Blood 109:4686-92. 2007
    ..032). The general recommendation of HSCT as first-line treatment option in chronic phase CML can no longer be maintained. It should be replaced by a trial with modern drug treatment first...
  17. ncbi [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]
    A Hochhaus
    III Medizinische Universitätsklinik, Klinikum Mannheim, Universitat Heidelberg, Wiesbadener Strasse 7 11, 68305 Mannheim
    Internist (Berl) 43:1228, 1231-8, 1241-4. 2002
  18. doi Comprehensive mutational profiling in advanced systemic mastocytosis
    Juliana Schwaab
    III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Mannheim, Germany
    Blood 122:2460-6. 2013
    ..019). We conclude that biology and prognosis in SM are related to the pattern of mutated genes that are acquired during disease evolution. ..
  19. ncbi Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome
    Silke Ulm
    III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany
    Onkologie 29:470-2. 2006
    ..Side effects which are seen in 1-10% of the vaccinated individuals are usually mild and consist of local reactions and constitutional symptoms. Since 1974, about 30 cases of vasculitis following influenza vaccination have been reported...
  20. ncbi Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
    G Metzgeroth
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Leukemia 21:1183-8. 2007
    ....
  21. ncbi Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection-case report and review of the literature
    O Maywald
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 68305, Mannheim, Germany
    Ann Hematol 83:189-94. 2004
    ..Possible mechanisms of this phenomenon are discussed with a review of the literature...
  22. ncbi Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea
    R Hehlmann
    Klinikum Mannheim, Universitat Heidelberg, Mannheim, Germany
    Leukemia 17:1529-37. 2003
    ..In view of the data of CML-study I, these results suggest that IFN/HU is also superior to IFN alone. HU should be combined with IFN in IFN-based therapies and for comparisons with new therapies...
  23. ncbi [Chronic myeloproliferative diseases. Diagnosis and therapy]
    E Lengfelder
    II Medizinische Klinik Mannheim, Universitat Heidelberg
    Internist (Berl) 44:1011-2, 1015-27; quiz 1028-9. 2003
    ..In CML, the decision-making analysis should be based on established scores. In BCR-ABL negative CMPDs an allogeneic stem cell transplantation should only be performed in patients with unfavorable prognosis...
  24. ncbi Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
    U Berger
    III Medizinische Universitätsklinik, Klinikum Mannheim, Universitat Heidelberg, Wiesbadener Strasse 7 11, 68305 Mannheim, Germany
    Ann Hematol 83:258-64. 2004
  25. ncbi Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
    U Berger
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim, Universitat Heidelberg, 68305 Mannheim, Germany
    Leukemia 19:984-9. 2005
    ..0006). This is the first analysis of gender aspects in CML using randomized trials. It demonstrates the relevance of analyses of gender differences in CML and in malignant disease at large...
  26. ncbi [Current pharmacotherapy of chronic myeloid leukemia]
    A Hochhaus
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Wiesbadener Strasse 7 11, 68305 Mannheim
    Internist (Berl) 43:270-83. 2002
  27. ncbi Peritoneal haematopoiesis in acute panmyelosis with myelofibrosis
    Georgia Metzgeroth
    III Medizinische Universitätsklinik, Klinikum Mannheim, University of Heidelberg, Germany
    Br J Haematol 130:1. 2005
  28. ncbi [Drug therapy of chronic myeloid leukemia]
    Andreas Hochhaus
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim
    Med Klin (Munich) 97:7-15. 2002
    ..91% of all CML patients in chronic phase achieve a hematologic remission within 11 months and 55% cytogenetic remission. In blast crisis, 29% achieve hematologic remission which may be durable...
  29. ncbi Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Gr
    A Hochhaus
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin, Mannheim der Universität Heidelberg, Mannheim, Germany
    Blood 95:62-6. 2000
    ..We suggest that for patients who reach CR, IFN should be continued at least until relatively low levels of residual leukemia are achieved. (Blood. 2000;95:62-66)..
  30. ncbi Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia
    O Maywald
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität, Heidelberg, Mannheim, Germany
    Leukemia 20:477-84. 2006
    ..We therefore conclude that allogeneic HSCT in CyR should be investigated prospectively as an alternative treatment option in defined patient groups...
  31. doi The molecular anatomy of the FIP1L1-PDGFRA fusion gene
    C Walz
    III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
    Leukemia 23:271-8. 2009
    ..The variability in the anatomy of the FIP1L1-PDGFRA fusion has important implications for strategies to detect the fusion at diagnosis or for monitoring response to treatment...
  32. ncbi The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
    C Walz
    III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, 68305 Mannheim, Germany
    Leukemia 19:1005-9. 2005
    ..MYO18A-FGFR1 is structurally similar to other fusion tyrosine kinases and is likely to be the causative transforming lesion in this unusual MDS/MPD...
  33. ncbi Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
    Amy V Jones
    Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, United Kingdom
    Blood 106:2162-8. 2005
    ..We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy...
  34. ncbi The results of imatinib therapy for patients with primary eosinophilic disorders
    Grzegorz Helbig
    Eur J Haematol 76:535-6. 2006
  35. doi Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders
    Nicholas C P Cross
    Wessex Regional Genetics Laboratory, University of Southampton, Salisbury District Hospital, Salisbury, UK
    Acta Haematol 119:199-206. 2008
    ....
  36. pmc The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
    Gerlinde Wernig
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Blood 111:3751-9. 2008
    ..Overall, our results suggest that constitutive activation of Jak2 requires an intact FERM domain for a transforming phenotype, and is necessary for activation of the major target of Jak2, STAT5...
  37. ncbi A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia
    Ulrike Bacher
    Department of Clinical Chemistry, Ludwig Maximilians University, Munich Marchioninistr 15, 81377 Munich
    Haematologica 91:817-20. 2006
    ..A FIP1L1-PDGFRA fusion gene was identified in four male patients by interphase FISH and RT-PCR. These methods in combination demonstrated clonality in 8/40 patients (20%) with a male predominance (6/8; 75%)...
  38. ncbi Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
    Amy V Jones
    Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, United Kingdom
    Blood 107:3339-41. 2006
    ..Our data indicate that, although PV patients may benefit from imatinib or rIFNalpha, molecular responses are relatively modest...
  39. ncbi Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
    Nicolaus Kroger
    Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, and Department of Hematology Oncology, University Hospital Regensburg, Germany
    Blood 109:1316-21. 2007
    ....
  40. ncbi Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia
    Claire E Curtis
    Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, UK
    Br J Haematol 138:77-81. 2007
    ..In conclusion, PDGFRA fuses to diverse partner genes in myeloid disorders. Identification of these fusions is important as they are particularly sensitive to imatinib...
  41. ncbi JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia
    Alwin Krämer
    Department of Internal Medicine V, University of Heidelberg, Heidelberg Germany
    Lancet Oncol 8:658-60. 2007
  42. ncbi The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA
    E Joanna Baxter
    Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, UK
    Hum Mol Genet 11:1391-7. 2002
    ..Our findings indicate that apparently simple cytogenetic variants of t(9;22) do not always mask a cryptic BCR-ABL fusion, even when found in association with clinical and haematological indications of CML...
  43. ncbi Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders
    Andreas Reiter
    Haematologica 92:1153-8. 2007
  44. ncbi Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib
    Norbert Frickhofen
    Department of Hematology Oncology, Dr Horst Schmidt Kliniken GmbH, Wiesbaden, Germany
    Ann Hematol 83:477-80. 2004
    ..Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib...
  45. ncbi Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses
    Jochen Utikal
    Department of Dermatology, Venereology, and Allergology, Central Laboratory, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Germany
    Arch Dermatol 143:736-40. 2007
    ..Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known...
  46. ncbi Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia
    Sebastian Kreil
    Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom
    Blood 110:1283-90. 2007
    ..007), age (P = .018), and spleen enlargement (P < .001) were significant independent indicators of survival and confirmed that only deletions spanning the ABL/BCR breakpoint were associated with an adverse prognosis (P = .039)...
  47. ncbi Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    Jelena V Jovanovic
    Department of Medical and Molecular Genetics, Guy s Hospital, King s College London, UK
    Blood 109:4635-40. 2007
    ....
  48. ncbi DNA topoisomerase II in therapy-related acute promyelocytic leukemia
    Anita R Mistry
    Department of Medical and Molecular Genetics, Guy s, King s, and St Thomas School of Medicine, London
    N Engl J Med 352:1529-38. 2005
    ..We studied acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or laryngeal cancer with chemotherapeutic agents that poison topoisomerase II...
  49. pmc A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples
    Martin Sattler
    Blood 107:1237-8. 2006